Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study

The Journal of Clinical Psychiatry
Robin EmsleyGuadalupe Martinez

Abstract

An unanswered question in the management of schizophrenia is how long antipsychotic treatment should be continued after a single psychotic episode. In this study, we assessed the rates of symptom recurrence with intermittent treatment in patients with a first episode of DSM-IV-defined schizophrenia or related illness after 2 years of successful continuous treatment. We also investigated antecedents of recurrence, as well as demographic and baseline clinical predictors of early recurrence, and we compared the psychopathology of the recurrence episode with that of the first episode. Outpatients in an academic psychiatric hospital setting (single site) who had responded well in an open-label study with risperidone long-acting injection were recruited for this intermittent treatment trial, and those who participated had their treatment tapered and discontinued over a period of up to 6 weeks, with follow-up for 3 years or until reemergence of symptoms. Open-label treatment with oral risperidone and risperidone long-acting injection was immediately reinstituted in the event of recurrence of symptoms. The study was conducted between February 2004 and March 2010. The primary outcome measure was symptom recurrence rate at 3 years. Parti...Continue Reading

Citations

Sep 21, 2013·International Journal of Psychiatry in Clinical Practice·Pedro AfonsoIvan Bernardo-Fernandez
Dec 31, 2014·International Journal of Psychiatry in Clinical Practice·Luis SanMariano Villar
Jun 13, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Chen-Chung LiuTzung-Jeng Hwang
Oct 8, 2013·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Robin Emsley
Apr 12, 2016·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Tak Lam LoDavid Castle
Dec 3, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·S HeresR Vauth
Jun 13, 2013·Schizophrenia Research·Robin EmsleyLaila Asmal
Oct 8, 2013·Schizophrenia Research·Robin Emsley, Wolfgang W Fleischhacker
Feb 12, 2013·BMC Psychiatry·Robin EmsleyBrian H Harvey
Dec 23, 2015·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Gabriela MatosRodrigo A Bressan
Nov 2, 2014·Therapeutic Advances in Psychopharmacology·Sofia BrissosVicent Balanzá-Martinez
Jul 25, 2014·Human Psychopharmacology·Takefumi SuzukiMasaru Mimura
Jan 24, 2020·Frontiers in Psychiatry·Gloria GiordanoSergio De Filippis
Jan 10, 2019·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·Martin LambertAnne Karow
Feb 4, 2021·European Psychiatry : the Journal of the Association of European Psychiatrists·Emily Laing, David Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here